Camber Pharmaceuticals recalled one lot of a drug for pneumocystis jiroveci pneumonia because of the contamination risk of Bacillus cereus.
The microbial contaminant risk in Camber's atovaquone oral suspension, USP 750 milligrams per 5 milliliters, can lead to "life-threatening infections such as endocarditis and necrotizing soft tissue infections," the FDA said. No adverse reactions have been reported as of March 31.
The contaminant usually causes food poisoning, according to Cleveland Clinic.